Drug Trial Radar · NCT05075408
To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
258
Actual
Start
Mar 18, 2022
Primary completion
Jan 4, 2024
Study completion Jan 4, 2024
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Oct 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the efficacy of nemolizumab compared to placebo at reducing the intensity of pruritus after a 12-week treatment period in adult hemodialysis participants with moderate to severe pruritus.
Conditions
- Chronic Kidney Disease Associated Moderate to Severe Pruritus
Interventions
NemolizumabDrug
Participants received a loading dose of 60 mg nemolizumab at Baseline followed by 2 Subcutaneous (SC) injections for a total dose of 30 mg nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.
NemolizumabDrug
Participants received 2 SC injections of 30 mg nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.
PlaceboDrug
Participants received 2 SC injections of 30 mg placebo-matched to nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Responders With an Improvement of Worst Itch Numeric Rating Scale (WI NRS) Greater Than and Equal to (>=) 4 From Baseline at Week 12Time frame: Baseline, Week 12
Locations
64 sites in 4 countries. Site status is shown where the registry gives one.
Galderma Investigational Site 9989
Bakersfield, California
Galderma Investigational Site 9991
Glendale, California
Galderma Investigational Site 7018
Glendale, California
Galderma Investigational Site 7015
La Palma, California
Galderma Investigational Site 9996
Los Angeles, California
Galderma Investigational Site 9978
Lynwood, California
Galderma Investigational Site 7017
Riverside, California
Galderma Investigational Site 9973
Tarzana, California
Galderma Investigational Site 7028
Victorville, California
Galderma Investigational Site 9964
Victorville, California
Galderma Investigational Site 7003
Whittier, California
Galderma Investigational Site 9971
Denver, Colorado
Galderma Investigational Site 9988
Bloomfield, Connecticut
Galderma Investigational Site 9980
Middlebury, Connecticut
Galderma Investigational Site 9970
Boca Raton, Florida
Galderma Investigational Site 7037
Coral Gables, Florida
Galderma Investigational Site 7026
Hollywood, Florida
Galderma Investigational Site 9965
Miami, Florida
Galderma Investigational Site7016
Miami, Florida
Galderma Investigational Site 7032
Sanford, Florida
Galderma Investigational Site 7004
Tampa, Florida
Galderma Investigational Site 7025
Tampa, Florida
Galderma Investigational Site 7027
Columbus, Georgia
Galderma Investigational Site 9983
Overland Park, Kansas
Galderma Investigational Site 9972
Wichita, Kansas
Galderma Investigational Site 9963
Roseville, Michigan
Galderma Investigational Site 7020
Edina, Minnesota
Galderma Investigational Site 9982
Minneapolis, Minnesota
Galderma Investigational Site 7035
Kansas City, Missouri
Galderma Investigational Site 9962
Las Vegas, Nevada
Galderma Investigational Site 7038
Fresh Meadows, New York
Galderma Investigational Site 9998
Great Neck, New York
Galderma Investigational Site 9995
The Bronx, New York
Galderma Investigational Site 7007
Winston-Salem, North Carolina
Galderma Investigational Site 9992
Roseburg, Oregon
Galderma Investigational Site 9999
Spartanburg, South Carolina
Galderma Investigational Site 9967
Chattanooga, Tennessee
Galderma Investigational Site 7039
Arlington, Texas
Galderma Investigational Site 7040
Dallas, Texas
Galderma Investigational Site 9966
El Paso, Texas
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.